Drug treatment options for the 2019-new coronavirus (2019-nCoV)
Drug treatment options for the 2019-new coronavirus (2019-nCoV)
复制标题
DOI：
10.5582/bst.2020.01020
复制
发表时间：
2020-02-01
影响因子：
5.5
通讯作者：
Lu, Hongzhou
中科院分区：
文献类型：
--
作者：
Lu, Hongzhou
截至2020年1月22日，全国25个省（区、市）共报告新型冠状病毒（2019-nCoV）病例571例。目前，没有针对人类和动物冠状病毒的疫苗或抗病毒治疗，因此，尽快确定药物治疗方案对于应对2019-nCoV疫情至关重要。现有的广谱抗病毒药物使用标准检测，筛选含有许多现有化合物或数据库的化学文库，以及基于对单个冠状病毒的基因组和生物物理理解重新开发新的特异性药物，这三种一般方法用于发现人类病原体冠状病毒的潜在抗病毒治疗。洛匹那韦/利托那韦、核苷类似物、神经氨酸酶抑制剂、瑞德西韦、肽（EK1）、阿比多尔、RNA合成抑制剂（如TDF、3TC）、抗炎药（如激素等分子）、中药（如疏风解毒胶囊、莲花清文胶囊）可能是2019-nCoV的药物治疗选择。然而，这些药物对新型冠状病毒的疗效和安全性仍需通过临床实验进一步证实。
As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), arbidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019-nCoV still need to be further confirmed by clinical experiments.